Viracta Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Viracta TherapeuticsDer Gewinn des Unternehmens wird voraussichtlich um 0.9% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 57.6% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich um 14.7% pro Jahr wachsen.

Wichtige Informationen

-0.9%

Wachstumsrate der Gewinne

14.7%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	24.5%
Wachstumsrate der Einnahmen	57.6%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	14 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Viracta Therapeutics names Mark Rothera as new CEO

Sep 19

Viracta Therapeutics gets European orphan drug designation for lymphoma combo treatment

Sep 07

Viracta Therapeutics GAAP EPS of -$0.28

Aug 09

Viracta Therapeutics files for $200M mixed shelf offering

May 28

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:VIRX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	30	-88	N/A	N/A	2
12/31/2025	4	-89	N/A	N/A	2
12/31/2024	N/A	-63	N/A	N/A	3
3/31/2024	N/A	-48	-37	-36	N/A
12/31/2023	N/A	-51	-40	-40	N/A
9/30/2023	N/A	-48	-38	-38	N/A
6/30/2023	N/A	-53	-35	-34	N/A
3/31/2023	N/A	-51	-35	-35	N/A
12/31/2022	N/A	-49	-36	-35	N/A
9/30/2022	N/A	-50	-35	-35	N/A
6/30/2022	N/A	-47	-39	-35	N/A
3/31/2022	N/A	-46	-37	-33	N/A
12/31/2021	N/A	-115	-23	-19	N/A
9/30/2021	N/A	-110	-20	-16	N/A
6/30/2021	N/A	-99	-13	-13	N/A
3/31/2021	N/A	-94	-10	-10	N/A
12/31/2020	N/A	-19	-16	-16	N/A
12/31/2019	N/A	-14	-10	-10	N/A
12/31/2018	1	-10	-6	-6	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: VIRX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: VIRX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: VIRX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: VIRXDie Einnahmen des Unternehmens (57.6% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: VIRXDie Einnahmen des Unternehmens (57.6% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von VIRX in 3 Jahren voraussichtlich hoch sein wird

Viracta Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 20% to US$7.00

Price target decreased by 36% to US$9.40

Price target decreased by 9.1% to US$14.00

Price target decreased to US$15.00

Price target decreased to US$21.40

Price target increased to US$31.50

Recent updates

New major risk - Revenue and earnings growth

Viracta Therapeutics Receives Written Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement for Continued Listing under Nasdaq Listing Rule 5450(a)(1)

Viracta Therapeutics, Inc. Appoints Michael Faerm as Chief Financial Officer

Viracta Therapeutics, Inc., Annual General Meeting, Jun 18, 2024

Insufficient new directors

Viracta Therapeutics, Inc. Reports Positive Topline Results from Stage 1 of the Pivotal Phase 2 NAVAL-1 Trial

Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan

New major risk - Revenue and earnings growth

Price target decreased by 20% to US$7.00

Viracta Therapeutics, Inc. Provides Clinical Update

Viracta Therapeutics Announces Interim Data from Phase 1B/2 Clinical Trial of Nana-Val in Patients with Epstein-Barr Virus-Positive Solid Tumors That Show Confirms Tumor Responses At Higher Dose Levels

Viracta Therapeutics, Inc. Receives A Written Notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market LLC

Viracta Therapeutics, Inc. Receives A Written Notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market LLC

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Viracta Therapeutics, Inc. Appoints Darrel P. Cohen, M.D., Ph.D. as Chief Medical Officer

Price target decreased by 36% to US$9.40

Price target decreased by 9.1% to US$14.00

Viracta Therapeutics’ Pivotal Naval-1 Trial Achieves Efficacy Threshold for Expansion in Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma

Viracta Therapeutics, Inc. Announces First Clinical Response in Epstein-Barr Virus-Positive (EBV+) Solid Tumor Setting and Outlines Key 2023 Clinical Objectives

Viracta Therapeutics, Inc. Announces Preliminary Dose-Ranging Data from the Phase 1B/2 Trial of Nana-Val in Patients

Price target decreased to US$15.00

High number of new directors

High number of new directors

High number of new directors

Viracta Therapeutics, Inc. Announces CEO Changes

Viracta Therapeutics names Mark Rothera as new CEO

Viracta Therapeutics gets European orphan drug designation for lymphoma combo treatment

CEO, President & Director exercised options and sold US$54k worth of stock

Viracta Therapeutics, Inc. Announces Resignation of Michael Huang as Director

Viracta Therapeutics Appoints Jane Chung, R.Ph., to its Board of Directors

Viracta Therapeutics GAAP EPS of -$0.28

Viracta Therapeutics, Inc.(NasdaqGS:VIRX) dropped from Russell 2500 Value Index

Viracta Therapeutics, Inc. Provides an Update on the Phase 1b/2 Trial of Nana-Val in Patients with Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors

Price target decreased to US$21.40

Less than half of directors are independent

Viracta Therapeutics, Inc. Announces That Gur Roshwalb Will Not Stand for Re-Election At the Company’s 2022 Annual Meeting of Stockholders

Price target increased to US$31.50

Viracta Therapeutics Announces First Patient Dosed in Phase 1b/2 Trial of Nana-val in Patients with Advanced Epstein-Barr Virus-Positive Solid Tumors

Viracta Therapeutics Announces Final Phase 1b/2 Data Showing Promising and Durable Signal of Efficacy for Nana-val in Relapsed/Refractory Epstein-Barr Virus-Positive Lymphoma in an Oral Presentation at ASH 2021

CEO, President & Director exercised options and sold US$133k worth of stock

Viracta Therapeutics Announces FDA Clearance of IND Application for Phase 1b/2 Trial in Epstein-Barr Virus-Positive (EBV+) Solid Tumors

Viracta Therapeutics, Inc. Announces the Initiation of Naval-1, A Global Pivotal Trial for the Treatment of Relapsed/Refractory Epstein-Barr Virus-Positive Lymphoma

Viracta Therapeutics files for $200M mixed shelf offering

Viracta Therapeutics, Inc. Announces Executive Changes

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken